Header Logo

Connection

Michael Ihnat to Humans

This is a "connection" page, showing publications Michael Ihnat has written about Humans.
Connection Strength

0.490
  1. AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1a stabilization. Cancer Lett. 2017 03 01; 388:149-157.
    View in: PubMed
    Score: 0.030
  2. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May; 353(2):392-404.
    View in: PubMed
    Score: 0.027
  3. Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy". PLoS One. 2013; 8(5):e64181.
    View in: PubMed
    Score: 0.024
  4. Synthesis and biological activity of 5-chloro-N4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. Bioorg Med Chem. 2013 Apr 01; 21(7):1857-64.
    View in: PubMed
    Score: 0.023
  5. N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorg Med Chem. 2012 Apr 01; 20(7):2444-54.
    View in: PubMed
    Score: 0.021
  6. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010 Aug; 27(8):862-7.
    View in: PubMed
    Score: 0.019
  7. Oxidative stress is, convincingly, the mediator of the dangerous effects of glucose variability. Diabet Med. 2010 Aug; 27(8):968.
    View in: PubMed
    Score: 0.019
  8. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia. 2007 Jul; 50(7):1523-31.
    View in: PubMed
    Score: 0.015
  9. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med. 2007 Jun; 24(6):582-6.
    View in: PubMed
    Score: 0.015
  10. A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization. BMC Cardiovasc Disord. 2007 Jan 18; 7:4.
    View in: PubMed
    Score: 0.015
  11. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007 May 08; 249(2):209-19.
    View in: PubMed
    Score: 0.015
  12. Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration. Toxicol Sci. 2005 Aug; 86(2):248-57.
    View in: PubMed
    Score: 0.013
  13. A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett. 2005 Jan 20; 217(2):171-80.
    View in: PubMed
    Score: 0.013
  14. Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett. 2021 06 01; 41:127923.
    View in: PubMed
    Score: 0.010
  15. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.
    View in: PubMed
    Score: 0.010
  16. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorg Med Chem. 2021 01 01; 29:115887.
    View in: PubMed
    Score: 0.010
  17. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res. 1999; 11(7):303-10.
    View in: PubMed
    Score: 0.009
  18. Geochemical characterization and renal cell toxicity of water-soluble extracts from U.S. Gulf Coast lignite. Environ Geochem Health. 2019 Apr; 41(2):1037-1053.
    View in: PubMed
    Score: 0.009
  19. Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. Bioorg Med Chem Lett. 2018 10 01; 28(18):3085-3093.
    View in: PubMed
    Score: 0.008
  20. Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
    View in: PubMed
    Score: 0.008
  21. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res. 1997 Aug; 3(8):1339-46.
    View in: PubMed
    Score: 0.008
  22. Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.
    View in: PubMed
    Score: 0.008
  23. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem. 2017 01 15; 25(2):545-556.
    View in: PubMed
    Score: 0.007
  24. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorg Med Chem. 2015 May 15; 23(10):2408-23.
    View in: PubMed
    Score: 0.007
  25. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
    View in: PubMed
    Score: 0.006
  26. Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT. Bioorg Med Chem Lett. 2013 Sep 15; 23(18):5049-52.
    View in: PubMed
    Score: 0.006
  27. Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor. Bioorg Med Chem Lett. 2013 Jun 15; 23(12):3561-4.
    View in: PubMed
    Score: 0.006
  28. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem. 2013 Mar 01; 21(5):1312-23.
    View in: PubMed
    Score: 0.006
  29. Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
    View in: PubMed
    Score: 0.005
  30. Hypoxia triggers a HIF-mediated differentiation of peripheral blood mononuclear cells into osteoclasts. Orthod Craniofac Res. 2012 Feb; 15(1):1-9.
    View in: PubMed
    Score: 0.005
  31. Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo. Bioconjug Chem. 2012 Jan 18; 23(1):115-24.
    View in: PubMed
    Score: 0.005
  32. N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. Bioorg Med Chem. 2012 Jan 15; 20(2):910-4.
    View in: PubMed
    Score: 0.005
  33. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid-poly(lactide-co-glycolide) nanoparticles: from fabrication to preclinical validation. J Biomed Mater Res A. 2010 Sep 01; 94(3):712-9.
    View in: PubMed
    Score: 0.005
  34. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med. 2010 Aug; 27(8):911-7.
    View in: PubMed
    Score: 0.005
  35. Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2010 Jul 15; 18(14):5261-73.
    View in: PubMed
    Score: 0.005
  36. The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorg Med Chem Lett. 2010 May 15; 20(10):3177-81.
    View in: PubMed
    Score: 0.005
  37. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 Mar 15; 70(6):2445-54.
    View in: PubMed
    Score: 0.005
  38. Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo. Altern Ther Health Med. 2010 Mar-Apr; 16(2):12-4.
    View in: PubMed
    Score: 0.005
  39. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. J Med Chem. 2010 Feb 25; 53(4):1563-78.
    View in: PubMed
    Score: 0.005
  40. Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorg Med Chem. 2009 Oct 15; 17(20):7324-36.
    View in: PubMed
    Score: 0.005
  41. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Mol Pharmacol. 2009 Sep; 76(3):588-95.
    View in: PubMed
    Score: 0.004
  42. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab. 2009 Aug; 94(8):2751-6.
    View in: PubMed
    Score: 0.004
  43. Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. J Thromb Haemost. 2009 Jul; 7(7):1228-30.
    View in: PubMed
    Score: 0.004
  44. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009 Feb; 94(2):410-5.
    View in: PubMed
    Score: 0.004
  45. Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress. Diabetes Res Clin Pract. 2008 Nov; 82(2):262-7.
    View in: PubMed
    Score: 0.004
  46. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev. 2008 May-Jun; 24(4):301-9.
    View in: PubMed
    Score: 0.004
  47. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2008 May 15; 16(10):5514-28.
    View in: PubMed
    Score: 0.004
  48. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008 Jun; 49(6):2679-85.
    View in: PubMed
    Score: 0.004
  49. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008 May; 57(5):1349-54.
    View in: PubMed
    Score: 0.004
  50. Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol. 2007 Mar 30; 7:4.
    View in: PubMed
    Score: 0.004
  51. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem. 2005 Sep 15; 13(18):5475-91.
    View in: PubMed
    Score: 0.003
  52. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. Bioorg Med Chem. 2003 Nov 17; 11(23):5155-70.
    View in: PubMed
    Score: 0.003
  53. Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorg Med Chem Lett. 2003 Mar 24; 13(6):1187-9.
    View in: PubMed
    Score: 0.003
  54. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull. 2002 May; 25(5):597-604.
    View in: PubMed
    Score: 0.003
  55. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol Carcinog. 1999 Jul; 25(3):219-29.
    View in: PubMed
    Score: 0.002
  56. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers. Mol Pharmacol. 1999 May; 55(5):938-47.
    View in: PubMed
    Score: 0.002
  57. Molecular basis for effects of carcinogenic heavy metals on inducible gene expression. Environ Health Perspect. 1998 Aug; 106 Suppl 4:1005-15.
    View in: PubMed
    Score: 0.002
  58. Binding of nuclear proteins associated with mammalian DNA repair to the mitomycin C-DNA interstrand crosslink. Environ Mol Mutagen. 1998; 31(1):70-81.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.